The global Vaccine Adjuvantsmarket was valued at USD 466.92 million in 2016 and is projected to reach USD 1140.32millionby 2025, growing at a CAGR of 10.43% from 2017 to 2025.
An adjuvant is a substance that is added to a vaccine to increase the body's immune response to the vaccine. Vaccines containing adjuvants are tested for safety in clinical trials before they are licensed for use. The increase in vaccine production activities by biopharmaceutical and healthcare sector, the market is expected to boost in forecast period.
Sample Infographics:
Market Dynamics:
1. Market Drivers
1.1 Increasing applications of Adjuvants in Vaccine technology
1.2 High Prevalence of Infectious diseases
1.3 Increase in instances of diseases and livestock practices
1.4 Increasing interest in Immunization Programs From Various Government Bodies
1.5 Technological Advancements in Aluminum Hydroxide-Based Adjuvants
1.6 Increasing Focus and Support on the Discovery and Development of Vaccine Adjuvants
1.7 Increasing Geriatric Population
2. Market Restraints
2.1 High Cost
2.2 Ethical restrains and stringent regulations regarding environment safety
Market Segmentation:
1. By Application Category:
1.1 Human Vaccine Adjuvants
1.2 Veterinary Vaccine Adjuvants
2. By Application:
2.1 Research Application
2.2 Commercial Application
3. By Disease Type:
3.1 Infectious Diseases
3.2 Cancer
3.3 Others
4. By Product Type:
4.1 Particulate Adjuvants
4.2 Adjuvant Emulsions
4.3 Pathogen Components
4.4 Combination Adjuvants
4.5 Others
5. By Route of Administration:
5.1 Intramuscular Route
5.2 Subcutaneous Route
5.3 Intranasal Route
5.4 Oral Route
5.5 Intradermal Route
5.6 Others
6. By Region:
6.1 North America (U.S., Canada, Mexico)
6.2 Europe (Germany, UK, France, Rest of Europe)
6.3 Asia Pacific (China, India, Japan, Rest of Asia Pacific)
6.4 Latin America (Brazil, Argentina, Rest of Latin America)
6.5 Middle East & Africa
Competitive Landscape:
The major players in the market are as follows:
1. BrenntagBiosector A/S (A Subsidiary of Brenntag AG)
2. Seppic (A Subsidiary of Air Liquide Group)
3. CSL Limited
4. Agenus, Inc.
5. Novavax, Inc.
6. Invivogen
7. SPI Pharma, Inc. (A Subsidiary of Associated British Foods PLC.)
8. Avanti Polar Lipids, Inc.
9. MVP Laboratories, Inc.
10. OZ Biosciences
These major players have adopted various organic as well as inorganic growth strategies such as mergers & acquisitions, new product launches, expansions, agreements, joint ventures, partnerships, and others to strengthen their position in this market.
RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE:
Research study on the Vaccine Adjuvantsmarketwas performed in five phases which include Secondary research, Primary research, subject matter expert advice, quality check and final review.
The market data was analyzed and forecasted using market statistical and coherent models. Also market shares and key trends were taken into consideration while making the report. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis.
To know more about the Research Methodology of Verified Market Intelligence and other aspects of the research study, kindly get in touch with our sales team.
1 INTRODUCTION OF GLOBAL VACCINE ADJUVANTSMARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions
2 EXECUTIVE SUMMARY
3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources
4 GLOBAL VACCINE ADJUVANTSMARKETOUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework
5 GLOBAL VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY:
5.1 Human Vaccine Adjuvants
5.2 Veterinary Vaccine Adjuvants
6 GLOBAL VACCINE ADJUVANTS MARKET, BY APPLICATION:
6.1 Research Application
6.2 Commercial Application
7 GLOBAL VACCINE ADJUVANTS MARKET, BY DISEASE TYPE:
7.1 Infectious Diseases
7.2 Cancer
7.3 Others
8 GLOBAL VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE:
8.1 Particulate Adjuvants
8.2 Adjuvant Emulsions
8.3 Pathogen Components
8.4 Combination Adjuvants
8.5 Others
9 GLOBAL VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION:
9.1 Intramuscular Route
9.2 Subcutaneous Route
9.3 Intranasal Route
9.4 Oral Route
9.5 Intradermal Route
9.6 Others
10 GLOBAL VACCINE ADJUVANTSMARKET, BY GEOGRAPHY
10.1 Overview
10.2 North AmericaRegional Market Estimates and Forecasts, 2012 - 2025
10.2.1 U.S.
10.2.2 Canada
10.2.3 Mexico
10.3 EuropeRegional Market Estimates and Forecasts, 2012 - 2025
10.3.1 Germany
10.3.2 U.K.
10.3.3 France
10.3.4 Rest of Europe
10.4 Asia PacificRegional Market Estimates and Forecasts, 2012 - 2025
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Rest of Asia Pacific
10.5 Latin AmericaRegional Market Estimates and Forecasts, 2012 - 2025
10.5.1 Brazil
10.5.2 Argentina
10.6 Rest of the WorldRegional Market Estimates and Forecasts, 2012 - 2025
11 GLOBAL VACCINE ADJUVANTSMARKETCOMPETITIVE LANDSCAPE
11.1 Overview
11.2 Company Market Share
11.3 Vendor Landscape
11.4 Key Development Strategies
12 COMPANY PROFILES
12.1 BrenntagBiosector A/S (A Subsidiary of Brenntag AG)
12.1.1 Overview
12.1.2 Financial Performance
12.1.3 Product Outlook
12.1.4 Key Developments
12.2 Seppic (A Subsidiary of Air Liquide Group)
12.2.1 Overview
12.2.2 Financial Performance
12.2.3 Product Outlook
12.2.4 Key Developments
12.3 CSL Limited
12.3.1 Overview
12.3.2 Financial Performance
12.3.3 Product Outlook
12.3.4 Key Developments
12.4 Agenus, Inc.
12.4.1 Overview
12.4.2 Financial Performance
12.4.3 Product Outlook
12.4.4 Key Developments
12.5 Novavax, Inc.
12.5.1 Overview
12.5.2 Financial Performance
12.5.3 Product Outlook
12.5.4 Key Developments
12.6 Invivogen
12.6.1 Overview
12.6.2 Financial Performance
12.6.3 Product Outlook
12.6.4 Key Developments
12.7 SPI Pharma, Inc. (A Subsidiary of Associated British Foods PLC.)
12.7.1 Overview
12.7.2 Financial Performance
12.7.3 Product Outlook
12.7.4 Key Developments
12.8 Avanti Polar Lipids, Inc.
12.8.1 Overview
12.8.2 Financial Performance
12.8.3 Product Outlook
12.8.4 Key Developments
12.9 MVP Laboratories, Inc.
12.9.1 Overview
12.9.2 Financial Performance
12.9.3 Product Outlook
12.9.4 Key Development
12.10 OZ Biosciences
12.10.1 Overview
12.10.2 Financial Performance
12.10.3 Product Outlook
12.10.4 Key Development
13 Appendix
13.1 Related Reports
Executive Summary
Azoth Analytics has released a research report titled "Global Cold Chain Equipment Market (2024 Edition)" which provides a complete analysis of the Global Cold Chain Equipment market in terms of market segmentation By Equipment Type (Refrigerators, Deep Freezers & Reef...
This report gives an insight into the global Agricultural Activator Adjuvants Market and predicts the future growth prospects and the trends that may exhibit in the market during the period of 2023-2030. The future growth has been calculated by taking into account the present growth rate and the ove...
Overview of the Global Vaccine Supply Chain Solutions Market:
The report discusses everything a marketer requires before investing in the global Vaccine Supply Chain Solutions Market during the forecast period 2023-...
Overview of the Global Digital Vaccine Tracking System Market:
The report discusses everything a marketer requires before investing in the global Digital Vaccine Tracking System Market during the forecast period 202...
Asia Pacific preventive vaccines market will grow by 7.9% annually with a total addressable market cap of $217.46 billion over 2023-2032, driven by the rising prevalence of several infectious diseases, rising R&D investment and technological advancement in vaccination technologies, rising need for p...
Europe preventive vaccines market was valued at $18.02 billion in 2022 and will grow by 5.1% annually over 2022-2032, driven by the rising prevalence of several infectious diseases, rising R&D investment and technological advancement in vaccination technologies, rising need for preventive vaccines s...
North America preventive vaccines market is projected to grow by 6.3% annually in the forecast period and reach $46.90 billion by 2032, driven by the rising prevalence of several infectious diseases, rising R&D investment and technological advancement in vaccination technologies, rising need for pre...
Global preventive vaccines market will reach $120.07 billion by 2032, growing by 6.4% annually over 2022-2032, driven by the rising prevalence of several infectious diseases, rising R&D investment and technological advancement in vaccination technologies, rising need for preventive vaccines such as ...
The global Mineral-based Adjuvants market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in t...
The global Whole Cell Cholera Vaccine market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players i...